A selective, nonsteroidal MR antagonist, finerenone, has been shown to represent a potential beneficial addition to the existing multifaceted strategy for CKD with T2D due to its favorable safety profile and effectiveness for alleviating cardiorenal complications in individuals with CKD and T2D [6]. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.